LAUSR

The severe acute respiratory syndrome coronavirus, popularly known as SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), has experienced fast global dissemination during the last 3 years and has resulted in unprecedented levels of illness and death throughout the globe. The persistent appearance of new SARS-CoV-2 different variants, which have increased infectivity, pathogenicity, transmissibility, and immunological disin-genuousness, has raised concerns about the ef fi ciency of coronavirus disease 2019 (COVID-19) vaccines as well as other therapeutic drugs such as monoclonal antibodies [1] . Since its fi rst appearance, the SARS-CoV-2 virus has undergone persistent and consistent mutation. Since the beginning of the pandemic, several distinct SARS-CoV-2 variations have been circulating. These SARS-CoV-2 variants vary somewhat from one variant to other in their capacity to produce respiratory infection during the acute phase of the virus. In the latter half of 2020, a variant with the name omicron fi rst appeared and quickly spread around the globe. Omicron has